Alnylam Pharmaceuticals Inc "RNAi Roundtable” Webcast Series: ALN-AGT, in Development for the Treatment of Hypertension Transcript
Good day, and welcome to the Alnylam Pharmaceuticals Roundtable Conference Call. Today's conference is being recorded.
At this time, I would like to turn the call over to Josh Brodsky. Please go ahead.
Good afternoon, everyone. Thank you for joining me for today's RNAi Roundtable, where we'll be discussing ALN-AGT, an RNAi therapeutic in development for the treatment at hypertension. I'm Josh Brodsky, Director of Investor Relations and Corporate Communications at Alnylam. With me today on the line are John Maraganore, Alnylam's Chief Executive Officer; Jae Kim, Vice President of Clinical Development; Lauren Melton, Senior Director and Program Leader for ALN-AGT; and Dr. Akshay Desai, Director of the Cardiomyopathy and Heart Failure Program in the Cardiovascular Division at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School.
Today's RNAi Roundtable is the first in a series of roundtable webinars that we'll be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
